Voyager Therapeutics, Inc.

NasdaqGS:VYGR

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 162.69 M

Share Price

USD 2.94

Avg Daily Volume

460,479

Change (1 day)

-1.01%

Change (1 year)

-63.66%

Change (YTD)

-48.15%

Voyager Therapeutics, Inc. Enterprise Value to EBITDA (EV/EBITDA) on June 23, 2025: 1.00

Voyager Therapeutics, Inc. Enterprise Value to EBITDA (EV/EBITDA) is 1.00 on June 23, 2025, a -106.98% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Voyager Therapeutics, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 10.14 on June 23, 2025, which is 910.48% above the current Enterprise Value to EBITDA (EV/EBITDA).
Voyager Therapeutics, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -126.51 on June 23, 2025, which is -12,708.19% below the current Enterprise Value to EBITDA (EV/EBITDA).
Voyager Therapeutics, Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -15.71.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NasdaqGS: VYGR

Voyager Therapeutics, Inc.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
IPO Date	Nov. 11, 2015
Location	United States
Headquarters	75 Sidney Street
Employees	172
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.